New recommendations on the use of products containing domperidone

HSA, in consultation with its Medicines Advisory Committee, has issued a Dear Healthcare Professional Letter to inform healthcare professionals about the new recommendations on the use of domperidone due to the potential risk of serious cardiovascular (CV) events associated with its use. HSA’s benefit-risk assessment took into consideration the long-established use of domperidone for the treatment of nausea, vomiting and dyspepsia, isolated CV events reported locally, the lack of suitable therapeutic alternatives, the input of local clinical experts and international regulatory actions. It was concluded that the benefit-risk profile of domperidone for treatment of dyspepsia, nausea and vomiting remains favourable if additional measures are taken to mitigate the risk of cardiotoxicity. Please refer to the letter for details.

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under ‘For Healthcare Professionals’.

Step 2: Click on ‘Useful links’.

Step 3: Click on ‘MOH Alert’ and log in via Singpass.

Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.